These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 34911327)

  • 1. Waldenström macroglobulinemia.
    Baďurová K; Gregorová J; Vlachová M; Krejčí M; Ševčíková S
    Klin Onkol; 2021; 34(6):428-433. PubMed ID: 34911327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How to Sequence Therapies in Waldenström Macroglobulinemia.
    Sarosiek S; Treon SP; Castillo JJ
    Curr Treat Options Oncol; 2021 Aug; 22(10):92. PubMed ID: 34426943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia.
    Wang Y; Gali VL; Xu-Monette ZY; Sano D; Thomas SK; Weber DM; Zhu F; Fang X; Deng M; Zhang M; Hagemeister FB; Li Y; Orlowski RZ; Lee HC; Young KH
    Neoplasia; 2021 Apr; 23(4):361-374. PubMed ID: 33735664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zanubrutinib for the treatment of Waldenström Macroglobulinemia.
    Lim KJC; Tam CS
    Expert Rev Hematol; 2020 Dec; 13(12):1303-1310. PubMed ID: 33297772
    [No Abstract]   [Full Text] [Related]  

  • 5. A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.
    Tam CS; LeBlond V; Novotny W; Owen RG; Tedeschi A; Atwal S; Cohen A; Huang J; Buske C
    Future Oncol; 2018 Sep; 14(22):2229-2237. PubMed ID: 29869556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review.
    Castillo JJ; Moreno DF; Arbelaez MI; Hunter ZR; Treon SP
    Expert Rev Hematol; 2019 Oct; 12(10):873-881. PubMed ID: 31343930
    [No Abstract]   [Full Text] [Related]  

  • 7. Emerging drugs for the treatment of Waldenström macroglobulinemia.
    Despina F; Meletios Athanasios D; Efstathios K
    Expert Opin Emerg Drugs; 2020 Dec; 25(4):433-444. PubMed ID: 32955949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia.
    Treon SP; Sarosiek S; Castillo JJ
    Blood; 2024 Apr; 143(17):1702-1712. PubMed ID: 38211337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete Response of a Young Woman With MYD88
    Pabon CM; Neff JL; Forns TE; Wang J
    Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e809-e812. PubMed ID: 32660904
    [No Abstract]   [Full Text] [Related]  

  • 10. Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia.
    Hunter ZR; Yang G; Xu L; Liu X; Castillo JJ; Treon SP
    J Clin Oncol; 2017 Mar; 35(9):994-1001. PubMed ID: 28294689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ibrutinib in previously treated Waldenström's macroglobulinemia.
    Treon SP; Tripsas CK; Meid K; Warren D; Varma G; Green R; Argyropoulos KV; Yang G; Cao Y; Xu L; Patterson CJ; Rodig S; Zehnder JL; Aster JC; Harris NL; Kanan S; Ghobrial I; Castillo JJ; Laubach JP; Hunter ZR; Salman Z; Li J; Cheng M; Clow F; Graef T; Palomba ML; Advani RH
    N Engl J Med; 2015 Apr; 372(15):1430-40. PubMed ID: 25853747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia.
    Treon SP; Meid K; Hunter ZR; Flynn CA; Sarosiek SR; Leventoff CR; White TP; Cao Y; Roccaro AM; Sacco A; Demos MG; Guerrera ML; Kofides A; Liu X; Xu L; Patterson CJ; Munshi M; Tsakmaklis N; Yang G; Ghobrial IM; Branagan AR; Castillo JJ
    Blood; 2021 Oct; 138(17):1535-1539. PubMed ID: 34289017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Treatment Strategies in the Management of Waldenström Macroglobulinemia.
    Zanwar S; Abeykoon JP; Kapoor P
    Curr Hematol Malig Rep; 2020 Feb; 15(1):31-43. PubMed ID: 32006301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical application of genomics in Waldenström macroglobulinemia.
    Branagan AR; Lei M; Treon SP; Castillo JJ
    Leuk Lymphoma; 2021 Aug; 62(8):1805-1815. PubMed ID: 33569985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection.
    Kapoor P; Paludo J; Ansell SM
    Curr Treat Options Oncol; 2016 Mar; 17(3):16. PubMed ID: 26942591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia.
    Treon SP; Cao Y; Xu L; Yang G; Liu X; Hunter ZR
    Blood; 2014 May; 123(18):2791-6. PubMed ID: 24553177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance.
    Varettoni M; Zibellini S; Defrancesco I; Ferretti VV; Rizzo E; Malcovati L; Gallì A; Porta MGD; Boveri E; Arcaini L; Candido C; Paulli M; Cazzola M
    Haematologica; 2017 Dec; 102(12):2077-2085. PubMed ID: 28983055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status.
    Cea M; Cagnetta A; Acharya C; Acharya P; Tai YT; Yang C; Lovera D; Soncini D; Miglino M; Fraternali-Orcioni G; Mastracci L; Nencioni A; Montecucco F; Monacelli F; Ballestrero A; Hideshima T; Chauhan D; Gobbi M; Lemoli RM; Munshi N; Treon SP; Anderson KC
    Clin Cancer Res; 2016 Dec; 22(24):6099-6109. PubMed ID: 27287071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of robust predictors for ibrutinib response by multiomics in MYD88-mutated Waldenström macroglobulinemia.
    Richardson K; Castillo JJ; Sarosiek SR; Branagan AR; Flynn CA; Meid K; Gustine JN; Liu X; Kofides A; Liu S; Wolf JL; Kacena KA; Patterson CJ; Guerrera ML; Tsakmaklis N; Treon SP; Hunter ZR
    Blood Adv; 2024 May; 8(9):2133-2137. PubMed ID: 38237078
    [No Abstract]   [Full Text] [Related]  

  • 20. Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenström Macroglobulinemia.
    Tawfiq RK; Abeykoon JP; Kapoor P
    Curr Hematol Malig Rep; 2024 Jun; 19(3):120-137. PubMed ID: 38536576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.